BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
ME Staff 8-k
BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other EventsItem 8.01Other Events.
On September 28, 2017, BeiGene, Ltd. issued a press release announcing preliminary data from the dose-verification portion of the ongoing Phase 1/2 trial of its investigational anti-PD-1 antibody BGB-A317 in Chinese patients with advanced solid tumors, presented at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China.Thefull text of this press release is filed as Exhibit 99.1to this Current Report on Form 8-K and is incorporated herein byreference.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
ExhibitNo.
Description
99.1
Press Release issued on September 28, 2017
BeiGene, Ltd. ExhibitEX-99.1 2 ex-99d1.htm EX-99.1 bgne_Ex99_1 Exhibit 99.1 BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO Cambridge,…To view the full exhibit click here About BEIGENE,LTD. (NASDAQ:BGNE) BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.